{"url_path":"/sec/syre/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000083-index.html","accession_number":"0001636282-26-000083","cik":"0001636282","ticker":"SYRE","issuer_name":"Spyre Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000083-index.html","primary_entity_key":"0001636282","primary_entity_name":"Spyre Therapeutics, Inc."},"word_count":156,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nSPY002 SKYLINE Part A Induction Topline Results\n\nOn June 15, 2026, Spyre Therapeutics, Inc. (“Spyre” or the “Company”) issued a press release announcing positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 for the treatment of moderately-to-severely active ulcerative colitis (“UC”).\n\nA copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as expressly set forth by specific reference in such filing."}